The only thing I'd add is that it is very difficult to understand. When we did the international comparison, we looked at two jurisdictions, France and Canada, to see if we could look at the reasons for decision. In other words, what were the reasons that resulted in a negative recommendation here in Canada for some medicines, and what were the reasons in France, let's say, for positive recommendations for the same drugs?
One of the things we found was, again, the question of what the role is. We found that it seems as though in France there is a value placed on the therapeutic value of the medicine, which means that if this works better for you because you can tolerate it, or if it works better for you because it has fewer side effects for a specific patient subpopulation, then those are the reasons that maybe France can recommend that drug for approval. Unfortunately, we just didn't see the same types of reasons—the same type of thought, I would say—going into the recommendations that resulted in negative listing here in Canada.